Eli Lilly’s stock surged to a fifth consecutive record high after the pharmaceutical company reported better-than-expected earnings and an optimistic outlook. The company’s strong performance was driven by increased sales of its diabetes drug, Trulicity, and its newer drugs, including cancer treatment Verzenio. Eli Lilly also raised its full-year earnings and revenue guidance.

$5 / month
ShortyPRO Monthly
Monthly ShortyPRO subscription:
  • No ads!
  • Full access to all categories:
    • Business
    • Tech
    • Health
    • Sport
    • Entertainment
    • World
+ All future updates and features!
Free trial
ShortyPRO Trial
ShortyPRO experience for two weeks:
  • No ads!
  • Full access to all categories:
    • Business
    • Tech
    • Health
    • Sport
    • Entertainment
    • World